Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5481097 | 0.85 | GRM5 (0.60) | GRM5NPC1RAB9AALDH1A1TP53 | |
| SCHEMBL4222892 | 0.82 | TP53 (0.43) | GRM5NPC1RAB9AALDH1A1TP53 | |
| SCHEMBL4232390 | 0.82 | GRM5 (0.60) | GRM5NPC1RAB9AALDH1A1TP53 | |
| SCHEMBL5488373 | 0.82 | GRM5 (0.42) | GRM5NPC1RAB9AALDH1A1TP53 | |
| SCHEMBL14363432 | 0.82 | GRM5 (0.60) | GRM5NPC1RAB9AALDH1A1TP53 | |
| SCHEMBL8234009 | 0.82 | GRM5 (0.42) | GRM5NPC1RAB9AALDH1A1TP53 | |
| SCHEMBL5481033 | 0.81 | GRM5 (0.46) | GRM5NPC1RAB9AALDH1A1TP53 | |
| SCHEMBL5482685 | 0.78 | GRM5 (0.40) | GRM5NPC1RAB9AALDH1A1TP53 | |
| SCHEMBL14363430 | 0.78 | GRM5 (0.40) | GRM5NPC1RAB9AALDH1A1TP53 | |
| SCHEMBL2959556 | 0.76 | GRM5 (1.00) | GRM5NPC1RAB9AALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259860-A1 | MGluR5 modulators V | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| WO-2007130824-A2 | FUSED HETEROCYLIC COMPOUNDS AND THEIR USE AS MGLUR5 MODULATORS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259860-A1 | MGluR5 modulators V | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259860-A1 | MGluR5 modulators V | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259860-A1 | MGluR5 modulators V | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259860-A1 | MGluR5 modulators V | GRM5, GRIK5, GRM2 | GRM5 1/4885NPC1 934/4885RAB9A 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.